SCHEMBL30749052

SCHEMBL30749052

C[C@@H]1CN(c2ncc(N3C(=O)C(C)(C)c4c(N)nc(CO)nc43)cc2F)C[C@H](C)O1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.35
SYK P43405 1/20 0.33
TNKS O95271 1/20 0.33
PARP1 P09874 1/20 0.33
PARP10 Q53GL7 1/20 0.33
TNKS2 Q9H2K2 1/20 0.33
PARP2 Q9UGN5 1/20 0.33
LRRK2 Q5S007 5/20 0.32
ALOX15 P16050 1/20 0.32
FFAR2 O15552 2/20 0.31
BTK Q06187 1/20 0.31
KDM4E B2RXH2 1/20 0.31
HTT P42858 1/20 0.31
PIK3CA P42336 1/20 0.30
MTOR P42345 1/20 0.30
AOC3 Q16853 1/20 0.30
MEN1 O00255 1/20 0.30
ALDH1A1 P00352 1/20 0.30
GAA P10253 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30748797 0.86 LRRK2 (0.30) TNKSPARP1PARP10TNKS2PARP2
SCHEMBL30748781 0.84 AOC3 (0.39) MAPK1SYKBTKPIK3CAAOC3
SCHEMBL30748737 0.78
SCHEMBL30749129 0.75 AOC3 (0.36) MAPK1SYKTNKSPARP1PARP10
SCHEMBL30748916 0.75 HDAC6 (0.34) SYKALOX15PIK3CAMTORAOC3
SCHEMBL30748800 0.73 AOC3 (0.38) MAPK1SYKTNKSPARP1PARP10
SCHEMBL30748735 0.73 AOC3 (0.36) SYKLRRK2BTKMTORAOC3
SCHEMBL31691334 0.72 HDAC6 (0.34) MAPK1SYKALOX15KDM4EMTOR
SCHEMBL30749040 0.72 TRPV1 (0.38) SYKLRRK2BTKALDH1A1
SCHEMBL31691300 0.71 AOC3 (0.34) BTKAOC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT MAPK1 2929/4885SYK 2316/4885TNKS 1034/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.